News

The Munich Eye1d
New Antisense Oligonucleotide Approved for Rare Disease Treatment
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Monthly Prescribing Reference1y
Wainua Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
The Food and Drug Administration (FDA) has approved Wainua™ (eplontersen ... to a ligand containing three N-acetyl galactosamine (GalNAc) residues to enable delivery of the ASO to hepatocytes.
Business Wire3mon
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU ...
MedPage Today1y
FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced ...
Seeking Alpha2y
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Positive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal disease with ...
Nasdaq1y
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeks Data further strengthen eplontersen's ...
National Institute for Health and Care Excellence6mon
Eplontersen for treating hereditary transthyretin-related amyloidosis
Eplontersen (Wainzua, AstraZeneca) is indicated for 'treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with stage 1 and 2 polyneuropathy'. The list price ...
Mena FN8mon
Eplontersen Approved To Treat Adults With Rare Inherited Nerve Disease Or Polyneuropathy
(MENAFN- Caribbean News Global) LONDON, England – The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainua) to treat adults with polyneuropathy associated ...
Business Insider1y
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Results from the week 66 primary analysis showed that eplontersen-treated patients demonstrated improvement across all co-primary and secondary endpoints, including serum transthyretin (TTR ...
Yahoo Finance8mon
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
Oct. 21, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for ...
Pharm Exec1y
AstraZeneca, Ionis Expand Eplontersen Agreement
After initially granting AstraZeneca the rights to eplontersen, an investigational antisense medicine that reduces the production of transthyretin protein (TTR) to treat transthyretin amyloidosis ...